Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224209 | 1.00 | SIGMAR1 (0.54) | SIGMAR1MAPTPOLBL3MBTL1KMT2A | |
| SCHEMBL1224358 | 0.85 | SIGMAR1 (0.48) | SIGMAR1MAPTPOLBL3MBTL1KMT2A | |
| SCHEMBL6988333 | 0.83 | SIGMAR1 (0.52) | SIGMAR1 | |
| SCHEMBL633889 | 0.83 | MAPT (0.50) | SIGMAR1MAPTPOLBKMT2A | |
| SCHEMBL633887 | 0.83 | MAPT (0.50) | SIGMAR1MAPTPOLBKMT2A | |
| SCHEMBL1223308 | 0.81 | MAOB (0.53) | MAPTL3MBTL1KMT2A | |
| SCHEMBL16162342 | 0.80 | MAPT (0.45) | MAPTKMT2AGRK2CTDSP1 | |
| SCHEMBL16162341 | 0.80 | MAPT (0.45) | MAPTKMT2AGRK2CTDSP1 | |
| SCHEMBL16469283 | 0.78 | LMNA (0.42) | SIGMAR1POLB | |
| SCHEMBL16469282 | 0.78 | LMNA (0.42) | SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| CN-101679415-B | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD | 2013-07-31 | — | — | CN | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
| CN-101679415-A | oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2144910-A2 | OXAZOLIDINONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | SIGMAR1 364/4885MAPT 4178/4885POLB 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.